Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

  • Alcobra Ltd.
  • Athersys Inc.
  • BioCryst Pharmaceuticals Inc.
  • Celldex Therapeutics Inc.
  • Cempra Inc.
  • Chimerix Inc.
  • Cyberonics Inc.
  • Cytori Therapeutics Inc.
  • Dendreon Corp.
  • Navidea Biopharmaceuticals Inc.
  • NeoStem Inc.
  • Omeros Corp.
  • Prosensa Holding N.V.
  • Sarepta Therapeutics Inc.
  • Tekmira Pharmaceuticals Inc.
  • Tetraphase Pharmaceuticals Inc.

Steve Brozak

WBB Securities

Image: Steve Brozak

Steve Brozak is the managing partner and president of WBB Securities, an investment bank and financial analytical firm engaged in the biotechnology, pharmaceutical and medical device sectors. Before cofounding WBB Securities, he worked for several Wall Street firms, including Salomon Brothers, Dean Witter, Cowen & Company, and Alex. Brown & Sons. As WBB Security's Senior Equity Analyst, Brozak has been acknowledged for his investment acumen and equity research performance by the major analyst ranking systems. In 2013, he was selected as the #2 ranked analyst in the pharmaceuticals sector by the StarMine/Financial Times Industry Analyst Awards system. The Wall Street Journal distinguished Brozak as its Best on the Street Medical Equipment and Supplies financial analyst in its 19th Annual Best on the Street Survey in 2011. In 2010, Brozak received StarMine Thompson Reuters/Financial Times Best Brokerage Analyst award for his selection of top-performing companies in the biotechnology space. With a 25-year track record in banking and analysis in the life sciences space, Brozak also works as media commentator on the life sciences sector on the web, on television, and in print media. Brozak served in the United States Marine Corps and now serves on the Secretary of the Navy's Navy and Marine Corps Retiree Council, where he focuses on healthcare, benefits and other veteran issues. He received a bachelor's degree and a master's degree in business administration from Columbia University, and also holds FINRA licenses 3, 7, 8, 24, 63, 65, 79, 86, 87 and 99.




Recent Interviews

Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak (11/13/14) What do you get when you combine a top-ranked industry analyst with a retired lieutenant colonel from the U.S. Marine Corp.? You get Steve Brozak, who brings his one-of-a kind perspective on the intricacies of Ebola virus disease to this interview with The Life Sciences Report. His military background, combined with 20 years as a biotech and medtech analyst, has allowed the WBB Securities cofounder to develop a reasoned perspective on how West Africa's Ebola epidemic might be humanely halted. Brozak also mentions small-cap names that could considerably enhance investors' portfolios.

Steve Brozak: Big-Picture Biotech Stocks Rule the Future (9/4/14) When Steve Brozak performs diligence on biotech stocks, he's always looking for an angle. Brozak, president and managing director at WBB Securities, wants to see how new technology platforms and novel ideas fit into tomorrow's healthcare system, which he believes will be unsustainable without therapies that work more efficiently and hold promise as true disease-modifying agents. In this interview with The Life Sciences Report, Brozak brings eight names to investors' attention. Given time, each holds the potential to be a huge gainer.

Do Away with the Pill-A-Day Biotech Model: Steve Brozak (2/6/14) The U.S. healthcare system is untenable, says Steve Brozak, president of WBB Securities. The solution-oriented Brozak is on the hunt for biotech and medical device companies that fit a new paradigm, in which budgets are restrained and companies generate curative therapies for unmet needs. In this interview with The Life Sciences Report, Brozak takes aim at a broken system and lists ten problem-solving companies that can adapt to the changes he believes must take place for healthcare to be profitable and productive. A bonus: These companies can also add vigor to investment portfolios.

Recent Quotes

"OMER's Omidria is FDA-approved, proven sterile and safe, and reimbursable by payers." (11/13/14) Omeros Corp. - The Life Sciences Report Interview with Steve Brozak More >

"NBS will announce results from its Phase 2b PreSERVE-AMI trial on Nov. 17." (11/13/14) NeoStem Inc. - The Life Sciences Report Interview with Steve Brozak More >

"I think it would be easy for OMER to single-handedly take the market." (2/6/14) Omeros Corp. - The Life Sciences Report Interview with Steve Brozak More >

"NBS' initial trial data has been positive beyond expectations." (2/6/14) NeoStem Inc. - The Life Sciences Report Interview with Steve Brozak More >

"We believe ATHX is still undervalued." (2/6/14) Athersys Inc. - The Life Sciences Report Interview with Steve Brozak More >

"There is exciting potential for CYTX's therapy." (2/6/14) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Steve Brozak More >

"We rate ATHX a Strong Buy for its fantastic progress in Japan and its continued positive work in the U.S." (1/9/14) Athersys Inc. - Steve Brozak, WBB Securities More >

"NBS has crossed the 50% enrollment mark on its PreSERVE-AMI phase 2 clinical trial; safety looks good and enrollment should be completed this year." (4/11/13) NeoStem Inc. - The Life Sciences Report Interview with Steve Brozak More >

more comments

"ATHX's partnership with Pfizer Inc. puts it in a remarkable position." (4/11/13) Athersys Inc. - The Life Sciences Report Interview with Steve Brozak More >

fewer comments


Due to permission requirements, not all quotes are shown.